Skip to main content
SpringerLink
Log in

The Role of Alpha-Glucosidase Inhibitors (Acarbose)

  • Chapter
Pharmacotherapy of Diabetes: New Developments

Keywords: acarbose, pharmacology, diabetes, metabolic syndrome, primary prevention, cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wallander M, Bartnik M, Efendic S et al. Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 2005;48(11):2229–2235.

    Article  CAS  PubMed  Google Scholar 

  2. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11 years follow-up. Diabetologia 1996;39(12):1577–1583.

    Article  CAS  PubMed  Google Scholar 

  3. Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164(19):2090–2095.

    Article  CAS  PubMed  Google Scholar 

  4. Burchfiel CM, Curb JD, Rodriguez BL et al. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994;25(5): 951–957.

    CAS  PubMed  Google Scholar 

  5. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26(3):688–696.

    Article  Google Scholar 

  6. Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34(1):146–154.

    Article  CAS  PubMed  Google Scholar 

  7. Scognamiglio R, Negut C, De Kreutzenberg SV et al. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112(2):179–184.

    Article  PubMed  Google Scholar 

  8. Rudofsky G, Reismann P, Schiekofer S et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kB activation in PBMCs. Horm Met Res 2004;36:630–638.

    Article  CAS  Google Scholar 

  9. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295(14):1681–1687.

    Article  CAS  PubMed  Google Scholar 

  10. Woerle HJ, Szoke E, Meyer C et al. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2006; 290(1):E67–E77.

    Article  CAS  PubMed  Google Scholar 

  11. Coutinho M, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):233–240.

    Article  CAS  PubMed  Google Scholar 

  12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837–853.

    Article  Google Scholar 

  13. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427–2443.

    Article  CAS  PubMed  Google Scholar 

  14. Salsburg DS. The UGDP study. JAMA 1971;218(11):1704–1705.

    Article  CAS  PubMed  Google Scholar 

  15. Goke B, Herrmann C, Goke R et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994;24(Suppl 3):25–30.

    PubMed  Google Scholar 

  16. Puls W. Pharmacology of glucosidase inhibitors. Oral Antidiabetics. Berlin: Springer, 1996;119:497–525.

    Google Scholar 

  17. Puls W, Keup U, Krause HP et al. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinemia. Naturwissenschaften 1977;64:536–537.

    Article  CAS  PubMed  Google Scholar 

  18. Schmidt DD, Frommer W, Junge B et al. Alpha-glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 1977;64: 535–536.

    Article  CAS  PubMed  Google Scholar 

  19. Krause HP, Ahr HJ. Pharmacokinetics and metabolism of glucosidase inhibitors. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharma–cology: Oral Antidiabetics. Vol. 119. Berlin: Springer, 1996;541–545.

    Google Scholar 

  20. Junge B, Matzke M, Stoltefuss J. Chemistry and structure–activity relationships of glucosidase inhibitors. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharmacology: Oral Antidiabetics. Vol. 119. Berlin: Springer, 1996;541–545.

    Google Scholar 

  21. Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism. Br J Clin Pharmacol 1990;30:391–396.

    CAS  PubMed  Google Scholar 

  22. Toeller M. Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In: Mogensen CE, Standl E, editors. Pharmacology of Diabetes. Berlin: De Gruyter, 1991;93–112.

    Google Scholar 

  23. Meneilly G, Ryan EA, Radziuk J et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23:1162–1167.

    Article  CAS  PubMed  Google Scholar 

  24. Hillebrand I, Boehme K, Frank G et al. Effects of the glycoside hydrolase inhibitor (BAY g 5421) on post-prandial blood glucose, serum insulin and triglycerides levels in man. In: Creutzfeldt W, editor. Frontiers of Hormone Research, the Entero-insular Axis. Basel: Karger, 1979;7:290–291.

    Google Scholar 

  25. Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732–737.

    Article  CAS  PubMed  Google Scholar 

  26. Chiasson JL, Josse RG, Leiter LA et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996;19:1190–1193.

    Article  CAS  PubMed  Google Scholar 

  27. Laube H, Linn T, Heyen P. The effects of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998;106:231–233.

    Article  CAS  PubMed  Google Scholar 

  28. Hanefeld M, Haffner SM, Menschikowski M et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract 2002;55:221–227.

    Article  CAS  PubMed  Google Scholar 

  29. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359(9323): 2072–2077.

    Article  CAS  PubMed  Google Scholar 

  30. Goke B, Fuder H, Wieckhorst G et al. Voglibose is an efficient alpha-glucosidase inhibitor and mobilize the endogenous GLP-1 reserve. Digestion 1995;56: 493–501.

    Article  CAS  PubMed  Google Scholar 

  31. Qualmann C, Nauck MA, Hoist JJ et al. Glucagon-like peptide 1 (GLP-1) [17–36 amide] secretion in response to luminal sucrose from the upper and lower gut: a study using a-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995;30:892–896.

    Article  CAS  PubMed  Google Scholar 

  32. Holman RR, Turner RC, Cull CA et al. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999;22:960–964.

    Article  CAS  PubMed  Google Scholar 

  33. Wolever TMS, Chiasson JL, Josse RG et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997;21:756–763.

    Article  CAS  PubMed  Google Scholar 

  34. Lindström J, Tuomilehto J, Spengler M. Acarbose treatment does not change the habitual diet of patients with type 2 diabetes mellitus. The Finnish Acarbose Study Group. Diabet Med 2000;17(1):20–25.

    Article  PubMed  Google Scholar 

  35. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002;22(10):695–701.

    Article  CAS  Google Scholar 

  36. Hanefeld M, Cagatay M, Petrowitsch T et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25(1):10–16.

    Article  CAS  PubMed  Google Scholar 

  37. Wascher TC, Schmoelzer I, Wiegratz A et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005;35(9):551–557.

    Article  CAS  PubMed  Google Scholar 

  38. Leonhardt W, Hanefeld M, Fischer S et al. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur J Clin Invest 1994;24(Suppl 3):45–49.

    PubMed  Google Scholar 

  39. Inoue I, Shinoda Y, Nakano T et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 2006;55(7):946–952.

    Article  CAS  PubMed  Google Scholar 

  40. Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732–737.

    Article  CAS  PubMed  Google Scholar 

  41. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002;45(4):461–475.

    Article  CAS  PubMed  Google Scholar 

  42. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose. Diabetes 2004;53(Suppl 2):A189.

    Google Scholar 

  43. Wang X, Lu J, Pan C. Comparison of serum C-reactive protein level in different glucose tolerance subjects and the change in serum CRP level in IGT subjects with acarbose. EASD 2003. Published in Chinese: Lu JM et al. Chin J Endocrinol Metab 2003;19:254–256.

    Google Scholar 

  44. Drent ML. Miglitol as single oral hypoglycemic agent in type 2 diabetes [Abstract]. Diabetologia 1994;37(Suppl 1):211.

    Google Scholar 

  45. Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from 5-year surveillance study. Diabetes Res Clin Pract 2001;2:193–204.

    Article  Google Scholar 

  46. Leboritz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132–145.

    Google Scholar 

  47. Hanefeld M, Fischer S, Julius U et al. and the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–1583.

    Article  CAS  PubMed  Google Scholar 

  48. Temelkova-Kurktschiev T, Kohler C, Henkel E et al. Post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbAlc level. Diabetes Care 2000;23:1830–1834.

    Article  CAS  PubMed  Google Scholar 

  49. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26(3):881–885.

    Article  PubMed  Google Scholar 

  50. May C. Efficacy and tolerability of step wise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM) treated with sulfonylureas. Diabetes Stoffwechsel 1995;4:3–7.

    Google Scholar 

  51. Fischer S, Hanefeld M, Spengler M et al. European study on dose–response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. 1998;35:34.

    CAS  Google Scholar 

  52. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.

    Article  CAS  PubMed  Google Scholar 

  53. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290(4):486–494.

    Article  CAS  PubMed  Google Scholar 

  54. Hanefeld M, Chiasson JL, Koehler C et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35(5):1073–1078.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Science and Technology Transfer, Centre for Clinical Studies, Fiedler Str. 34, 01307, Dresden, Germany

    Markolf Hanefeld & Frank Schaper

Authors
  1. Markolf Hanefeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Schaper
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Aarhus University Hospital, Nørrebrogade 44, DK-8000, Aarhus, Denmark

    Carl Erik Mogensen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hanefeld, M., Schaper, F. (2007). The Role of Alpha-Glucosidase Inhibitors (Acarbose). In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-69737-6_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-69736-9

  • Online ISBN: 978-0-387-69737-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation